The systemic treatment of patients with soft tissue sarcomas is an area of controversies where small progress has been made over the past years. The rarity of the disease in addition to the huge diversity of subtypes is probably to be responsible for the sometimes conflicting data obtained in clinical trials. Data presented on this year’s ASCO meeting dealt with the benefit from adjuvant treatment and with the concept of highdose consolidation therapy after complete surgical resection of a metastatic disease. The results of these trials lend support to the notion that systemic adjuvant treatment requires a rigorous patient selection and that dose escalation does not confer to a survival benefit in a situation of minimal residual disease. The more detailed understanding of pathognomonic alterations in sarcomas initiated early clinical trials with molecular directed therapies, which will probably invigorate our therapeutical possibilities.
Similar content being viewed by others
References
Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S and Parkinson DR (1993). Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11(7): 1269–1275
Adjuvant chemotherapy for localized resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma meta-analysis collaboration. Lancet, 350(9092): 1647–1654, 1997
Sarcoma meta-analysis collaboration (SMAC). Adjuvant chemotherapy for localized resectable soft tissue sarcoma in adults. Cochrane Database Syst Rev 2000(4): CD001419.
Stojadinovic A, Leung DH, Hoos A, Jaques DP, Lewis JJ and Brennan MF (2002). Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg 235(3): 424–434
Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS and Evans HL (2003). Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1,225 patients. Cancer 97(10): 2530–2543
Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A and Ghert M (2008). A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 113(3): 573–581
Guillou L, Benhattar J, Bonichon F, Gallagher G, Terrier P and Stauffer E et al (2004). Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol 22(20): 4040–4050
Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J and Radford J et al (2005). Phase II study of ET-743 in advanced soft tissue sarcomas: a european organisation for the research and treatment of cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 23(3): 576–584
Scotlandi K and Picci P (2008). Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opin Oncol 20(4): 419–427
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bechter, O.E. Systemic therapy of soft tissue sarcomas – “nothing new under the sun?” – ASCO 2009. memo 2, 208–210 (2009). https://doi.org/10.1007/s12254-009-0164-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12254-009-0164-0